Summary
On April 8, 2026, Jasveen Sangha, known in drug networks as the “Ketamine Queen,” was sentenced to 15 years in federal prison for her role in supplying the ketamine that…
Perry became addicted to ketamine during infusions at a clinic designed to help him with anxiety and depression.
Key points
- On April 8, 2026, Jasveen Sangha, known in drug networks as the “Ketamine Queen,” was sentenced…
- Perry became addicted to ketamine during infusions at a clinic designed to help him with anxiety…
- The network involved multiple participants: the manufacturing source (Sangha), the mid-level dealer (Fleming), the immediate distributor…
- What emerges from the court record is a functioning drug distribution network that had been operating…
On April 8, 2026, Jasveen Sangha, known in drug networks as the “Ketamine Queen,” was sentenced to 15 years in federal prison for her role in supplying the ketamine that killed “Friends” actor Matthew Perry in October 2023. Sangha pleaded guilty to one count of maintaining a drug-involved premise, three counts of distribution of ketamine, and one count of distribution of ketamine resulting in death. The sentencing resolved the most publicly visible element of a drug network that operated with sufficient openness and institutional tolerance that it took a celebrity death to generate criminal prosecution.
The Network Structure
Perry became addicted to ketamine during infusions at a clinic designed to help him with anxiety and depression. When he requested increased dosages that the clinic declined to provide, he turned to alternative sources. Sangha sold 51 vials of ketamine to a dealer named Erik Fleming, who sold them to Perry through the actor’s live-in personal assistant, Kenneth Iwamasa. On October 28, 2023, Iwamasa injected Perry with at least three shots of Sangha’s ketamine, causing his death from acute effects of the drug.
The network involved multiple participants: the manufacturing source (Sangha), the mid-level dealer (Fleming), the immediate distributor (Iwamasa), and two physicians (Mark Chavez and Salvador Plasencia) who facilitated Perry’s initial addiction through overprescription and then profited from his subsequent desperation. All five individuals charged in connection with Perry’s death pleaded guilty to their respective roles.
What emerges from the court record is a functioning drug distribution network that had been operating for years before Perry’s death, with Sangha “storing, packaging, and distributing narcotics,” including ketamine and methamphetamine, since at least 2019. The network was not hidden from law enforcement or from the broader Los Angeles community. It operated with sufficient openness that Perry’s assistant could access substantial quantities of prescription drugs through the network, sufficient openness that multiple doctors could coordinate in facilitating Perry’s addiction, sufficient openness that celebrity clients could source drugs through the network.
Celebrity Access and Institutional Enablement
The Perry case reveals a specific vulnerability in celebrity drug networks: celebrities possess substantial financial resources and social influence that allow them to acquire drugs more easily than average people. Additionally, some celebrities exploit a system of “VIP treatment” from certain doctors willing to bend medical rules or overprescribe medications to famous clients. The network that supplied Perry was structured precisely to serve this celebrity clientele.
What distinguished Perry’s case from countless similar networks operating in Los Angeles and other major cities was not the network’s sophistication or scale, but simply that a celebrity died and the government decided to prosecute. Drug networks that supply non-celebrity clients operate with minimal law enforcement attention. Celebrity networks operate with minimal law enforcement attention until the celebrity dies. Then, suddenly, the network becomes visible, the participants become prosecutable, and the systemic failures that enabled the network become temporarily discussable.
The Perry case is resolved with Sangha sentenced and network participants prosecuted. But the larger network—the one that supplies celebrities still living, still using, still accessing drugs through the same channels—continues operating. Nothing in the Perry prosecution fundamentally altered the conditions that allowed Sangha’s operation to function for years. Nothing prevented similar networks from operating parallel to the prosecution.
The POV
The Matthew Perry drug network case exposes an uncomfortable truth: celebrity drug supply networks operate in plain sight because governments tolerate them until a death forces intervention. Sangha was not operating a secret cartel hidden from law enforcement. She was operating a known drug distribution point in Los Angeles, apparently tolerated by local law enforcement, apparently profitable enough to sustain over multiple years, apparently protected by the commercial demand that celebrity clients provided. Perry’s death converted an operating drug network into a prosecutable crime scene. But the network had been operating successfully before Perry died. It presumably continues operating afterward, serving clients less famous and less likely to generate prosecution if they overdose.
The 15-year sentence imposed on Sangha is a genuine accountability measure. But it is accountability only because Perry was famous enough that his death generated media attention and prosecutorial resources. The vast majority of drug deaths do not result in this level of institutional response. The vast majority of drug networks do not face prosecution. Celebrity drug networks are only prosecutable when a celebrity dies and their death becomes public knowledge. The Perry case reveals that American drug enforcement operates primarily as celebrity death prevention, not as drug supply disruption. Networks continue operating. Deaths continue occurring. But governments only respond when the dead person matters enough to generate political pressure for prosecution.
The Perry case should also prompt a reckoning with how celebrity wealth distorts drug enforcement. Sangha’s network operated for years, supplying multiple clients, before investigators moved. The financial resources Perry’s assistant had access to — reportedly tens of thousands of dollars spent on ketamine in weeks — were a direct enabler. When money eliminates every friction that might slow a drug habit, the only remaining safeguard is enforcement. And as this case demonstrates, enforcement waited until a celebrity was dead in a hot tub. The fifteen-year sentence for Sangha is significant, but the structural conditions that made the network possible — available supply, wealthy demand, and institutional hesitation — remain unchanged.
What this means
The network involved multiple participants: the manufacturing source (Sangha), the mid-level dealer (Fleming), the immediate distributor (Iwamasa), and two physicians (Mark Chavez and Salvador Plasencia) who facilitated Perry’s initial addiction through overprescription and then profited from…
What emerges from the court record is a functioning drug distribution network that had been operating for years before Perry’s death, with Sangha “storing, packaging, and distributing narcotics,” including ketamine and methamphetamine, since at least 2019.
Bottom line
The Perry case reveals a specific vulnerability in celebrity drug networks: celebrities possess substantial financial resources and social influence that allow them to acquire drugs more easily than average people.